Matricelf Continues Clinical Execution with Patient Enrollment Preparation Following GLP Safety Success and GMP Manufacturing Milestones

Approval from Loewenstein Medical Center enables patient identification for Company's planned first-in-human spinal cord injury study TEL AVIV, Israel, July 9, 2026 /PRNewswire/ -- Matricelf Ltd. (TASE: MTLF), a regenerative medicine company developing personalized, autologous engineered...

Summary aggregated from PR Newswire's public RSS feed. The full reporting belongs to PR Newswire — please read it on their site.